



In Ovo translational model for functional assessment of probiotics through metabolome analysis

K. Stadnicka¹, S. Zuo¹, E. Samborowska², M. Radkiewicz², K. Grudlewska-Buda¹, K. Skowron¹

¹Nicolaus Copernicus University, Collegium Medicum, Jagiellońska 13/15, 85-067 Bydgoszcz, Poland

²IBB Polish Academy of Sciences, Mass Spectrometry Laboratory, , Pawińskiego 5A, 02-106 Warsaw, Poland





Candidate/ probiotics, beneficial microbial products, phytobiotics, have known benefits but mechanism unclear


Gap in knowledge and techniques → need for translational models linking *in vitro* and *in vivo* effects

→ evidence-based development of strategies to manage health by nature based solutions: bioactive compounds, immunomodulators

In vitro tests → early life/prenatal treatment → life long track of effects


Study Objectives

- Characterize metabolite changes in **chicken intestinal cell line** (Chick8E11) treated with *Bifidobacterium lactis* NCC2818 [Akhavan et al., 2023, Frontiers in Microbiology]
- Analyze metabolome changes in **gut content** of chickens injected *in ovo* with *B. lactis* alone or in a synbiotic combination of *B. lactis* with Astragalus polysaccharides synbiotic (Xi'an Weizhen Biotechnology Co., Ltd.)
- Establish correlations between *in vitro* and *in ovo/in vivo* models
- Identify key metabolic pathways affected by probiotic treatment



The pairs of candidate probiotic (n=2) and prebiotic (n=2) compounds were selected *in vitro* by testing 12 prebiotics and 12 probiotics:

Candidate Prebiotics	Candidate Probiotics
P1 Beta glucan	<i>Lactobacillus plantarum</i>
P2 Vegetable protein hydrolysate	<i>Bifidobacterium lactis</i>
P3 Liquid seaweed extract	<i>Lactobacillus rhamnosus</i>
P4 Short chain inulin	<i>Lactobacillus plantarum</i>
P5 Long chain inulin	<i>Carnobacterium divergens</i>
P6 Raffinose	<i>Propionibacterium thoenii</i>
P7 Galactooligosaccharides	<i>Clostridium butyricum</i>
P8 Snow crab chitooligosaccharides	<i>Bacillus strain</i> (5 were tested)
P9 Saccharicterpenin	
P10 Lentinus	
P11 Mannan oligosaccharides	P1: F981M156B, P2: B001P335, P3: A114P252 (BioAtlantis Ltd.)
P12 <u>Astragalus polysaccharides</u>	





The one-way ANOVA with Tukey's test as post hoc (Newman-Keuls) comparisons ($p \leq 0.05$). Blue arrows show stimulation of the probiotic growth and red arrows show the inhibition of the probiotic growth compared to the control variant (C: Control with glucose)

Co-cultures: The intestinal cells (Chic-8E11, Tentamus Pharma & Med Deutschland GmbH) were inoculated with the *Bifidobacterium lactis* (10:2 [CFU: cells] ratio) and cell free supernatants (CFS, at 20% v/v) derived from probiotic cultures that were adjusted to 10^6 CFU

The *Bifidobacterium* CFS were produced by collecting the probiotic culture supernatants followed by centrifugation at 10,000 x g for 10 min and filtration through a 0.45 μ m pore size filters (Millipore, Merck Group, Poland)

Co-cultures were maintained for 24h at 37°C, 5% CO₂ in in a complete DMEM/F12 medium, 3 independent experiments (biological repetitions) per each combination





In ovo injections were performed automatically to the amnion, using the Vinovo vaccination technology (Contributor: Viscon Group, Gravendeel The Netherlands). All the embryos were vaccinated (IBD, Phivax)


50 µl/egg,
140 eggs/group
18.5 day of embryonic incubation






Body Weights



(4 replicates per group, 15 birds per pen) with females only




Partial Least Squares Regression-DA plot




Individual samples are shown in columns and metabolites in rows

Component 2 (12,0 %) - Metabolic Complexity

Sparse Partial Least Squares Regression-DA plot



Component 1 (13,6%) - Metabolic Variation Score




- distinct metabolic signatures for each treatment group
- treatment-specific metabolite clustering patterns
- synbiotic treatment provides the most balanced metabolic profile
- changes represent metabolic adaptations rather than clear "beneficial" or "harmful" effects




Metabolite Class	Metabolite	Probiotic	Prebiotic	Synbiotic	Functional significance
Antioxidants	GSH constituents	++	++	+++	Cellular protection, detoxification
	Cysteine synthesis	+++	+	++	Supports antioxidant production
Amino Acids	Citrulline	+	++	+++	Nitric oxide (NO) cycle, mucosal barrier regulation
	Ornithine	+	++	+++	Ammonia detoxification
Energy metabolism	Lactic acid	+++	+	++	Antimicrobial, energy substrate
	Glutamine	+	++	+++	Primary enterocyte fuel
Barrier function	Anserine synthesis	+++	+++	+	Antioxidant, pH buffering
	Pro hydroxylation	+++	++	++	Collagen stability
Lipid metabolism	Fatty acids	+	++	+++	Membrane integrity, signaling
Bile Acids	Deoxycholic acid	+	++	+	Reduced inflammation


+Low levels ++ Moderate levels +++ High levels




Enrichment Overview (top 25)



Enrichment Overview (top 25)




Pathways affected between control cells and cells treated with *Bifidobacterium lactis* CFS



→ most significant pathways: amino acid metabolism, TCA cycle




Pathways affected between control cells Chic-8E11 and cells co-cultured with *Bifidobacterium lactis*





→ differential activation patterns between direct contact vs. supernatant

Enrichment Overview (top 25)




Enrichment Overview (top 25)



← probiotic-specific pathway activation




Metabolic pathways affected by differential metabolite enrichment between control and synbiotic group (10^3 CFU *Bifidobacterium* + 1 mg Astragalus polysaccharides),



← synergistic effects not seen in single treatments
← consistent metabolic pathway activation patterns across experimental models with enhanced effects in synbiotic treatment

Validating the translational model: In Vitro to In Ovo


Key metabolite comparison table



Metabolite Class	Key Metabolites	In Vitro Model	In Ovo Model	Functional Significance
Carboxylic Acids	Lactic acid	↑ in co-culture	↑ in probiotic group	Antimicrobial, energy source
	Succinate	↑ in co-culture	↑ in probiotic & synbiotic	Energy metabolism, homeostasis
Antioxidants	GSH constituents	↑ in both treatments	↑↑ in synbiotic group	Cellular protection, detoxification
	Cysteine	↑ in both treatments	↑ in probiotic group	Host's antioxidant defense capacity
Amino Acids	Glutamine/Glutamate	↑ in both treatments	↑↑ in synbiotic group	Enterocyte energy, barrier function
	Ornithine	↑ with supernatant	↑↑ in synbiotic group	Nitrogen metabolism
Growth Factors	Polyamines	↑ in both treatments	↑ in probiotic & synbiotic	Cell growth, differentiation
	β-Alanine	↑ in both treatments	↑ in probiotic group	Carnosine synthesis

- Metabolite consistency
- Pathway conservation
- Model complementarity


Functional significance of metabolic alterations



Integrating Metabolomics & Metagenomics

Enhanced intestinal barrier integrity


In vitro study:



Barrier Function Enhancement

Metagenomic data, in ovo:

Lactobacillus → GABA




MECHANISM:

- Occludin gene significantly up-regulated ($p < 0.01$) in Chick-8E11 cells with *B. lactis* treatment
- GABA production ($\uparrow$ 5.2-fold, $p < 0.05$)
- Lactobacillus strengthens tight junctions through occludin expression
- Synbiotic treatment increases beneficial Lactobacillus abundance that directly supports barrier function

Anti-inflammatory effects


Metabolomic evidence:

Significant lactate elevation with *B. lactis* treatment



Metagenomic suport:

Reduced abundance of inflammatory-associated bacteria
(*Staphylococci*, *Streptococci*, *Corynebacteria*)




Mechanism: Lactate production by beneficial bacteria inhibits pathogens and modulates immune response

Anti-inflammatory effects are achieved through both direct metabolite action and suppression of pathogenic bacteria

Host- mediated effect

Carboxylic Acid increases in Chick8E11 cells
after *B. lactis* treatment



All treatment conditions show statistically significant increases ($p < 0.01$) compared to control


← Carboxylic acids, important for cellular energy metabolism show increases after *B. lactis* treatment.

← Direct co-culture shows stronger effects

B. Lactis showed lower diversity of microbial community →


Synbiotic group showed a more balanced microbial interaction →

Shannon Index, gut samples




Integrative Model

Combining metabolomics and metagenomics explained the mechanisms of probiotic action



Translational, predictive model linking in vitro and in ovo effects



Ovobiom Acknowledgements



Krzysztof
Skowron



Katarzyna
Hrynkiewicz



Waldemar
Studziński



Cinzia
Randazzo



Giuseppe
Maiorano



Niloofar
Akhavan



Sanling
Zuo



Mengjun
Wu



Mariam
Ibrahim



Anna
Bajek



Research is funded by the Polish National Science Centre 2019/35/B/NZ9/03186-Ovobiom.



Università
di Catania



UNIVERSITÀ
DEGLI STUDI
DEL MOLISE